Top news from MedWatch this week

Monday
Lundbeck sells rights to three development programs
Preclinical hemophilia drug triggers USD 15m milestone payment from Novo Nordisk
Tuesday
ALK CEO urges calm after taking a beating from investors
Bavarian Nordic faces headwinds, maintains Danish Covid-19 vaccine was ”the right decision”
WSA raises full-year expectations
Wednesday
President of Demant subsidiary Interacoustics resigns
Strong phase II results could increase pace of Lundbeck’s new migraine candidate
Lundbeck raises operating profit expectation after booking its highest quarterly revenue
Thursday
FDA approves Lundbeck and Otsuka’s agitation treatment for Alzheimer’s patients
Lundbeck CEO: Great pleasure bagging crucial approval
Friday
Coloplast wants data on new ostomy product before deciding market viability
EU report recommends healthcare investments based on experiences from Covid-19